 First MSC study in acute GVHD to meet primary efficacy endpoint  There are no approved therapies for acute GVHD in children <12 years  Day 28 overall response was 69.1%; 74.5% and 68.5% were alive at days 100 and 180  Day 28 overall response strongly predicted day 100 survival  Remestemcel-L is a promising therapy in pediatric steroid refractory aGVHD A Phase 3, Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Abstract Word count: 283 ABSTRACT Steroid-refractory acute graft-versus-host disease (SR-aGVHD) following hematopoietic cell transplantation (HSCT) is associated with poor clinical outcomes. Currently, there are no safe and effective therapies approved for use in the pediatric population under the age of 12 years. Accordingly, there is an urgent need for new treatments that are safe, well-tolerated and effective in managing this debilitating and potentially fatal complication of HSCT. In early phase clinical trials, Mesenchymal stromal cells (MSCs) have demonstrated efficacy in the treatment of acute GVHD (aGVHD) in pediatric patients. We now report the results of a phase 3, prospective, single arm, multicenter study (NCT02336230) in 54 children with primary SR-aGVHD who were naïve to other immunosuppressant therapies (IST) for aGVHD treated with MSC product (remestemcel-L) dosed at 2 x 10 6 cells/kg twice weekly for four weeks. Remestemcel-L therapy significantly improved day 28 overall response rate (OR) compared to the pre-specified control OR value of 45% (70.4% versus 45%, P =0.0003). The statistically significant OR (70.4%) was sustained through day 100 including an increase in complete response (CR) from 29.6% at day 28 to 44.4% at day 100. Overall survival was 74.1% at day 100 and 68.5% at day 180. Overall response in all participants at day 28 was highly predictive of improved survival through 180 days and survival was significantly greater in day 28 responders compared with non-responders through day 100 (86.8% vs. 47.1% for responders and non-responders, respectively, P = 0.0001) and through day 180 (78.9% vs. 43.8%, p = 0.003). Remestemcel-L was well-tolerated with no identified infusion-related toxicities or other safety concerns. This study provides robust, prospective evidence of the safety, tolerability and efficacy of remestemcel-L as first-line therapy after initial steroid failure in pediatric SR-aGVHD.
INTRODUCTION
Acute graft-versus-host disease (aGVHD) is a major obstacle to the overall success of allogeneic hematopoietic stem cell transplantation (HSCT). Although the incidence of aGVHD varies across transplant type and donor sources, severe aGVHD (determined by grade C/D, visceral organ and/or multi-organ involvement, or high risk stratification) is associated with the highest risk of primary treatment failure and highest transplant related mortality. 1, 2 Mortality can reach as high as 90% in adults and children who fail to respond to initial steroid therapy. [2] [3] [4] [5] Despite overall improvement in transplantation outcomes, 6 the cohort of patients who develop aGVHD and subsequently fail to respond to initial steroid therapy continue to have high morbidity and mortality in large part because there are no effective treatment options for these patients. Two recent reports highlight the poor prognosis and consequent therapeutic gap in the management of pediatric aGVHD, in particular among children who fail to respond to initial steroid therapy and have more severe disease based on organ involvement. [7] [8] An exploratory analysis of outcomes in 203 steroid-refractory aGVHD patients including 61 children up to 18 years of age reported a 34% day 28 overall response rate (95% confidence interval 23-48%); overall 2-year survival in this cohort was 32%. 7 In a cohort of 370 pediatric aGVHD patients, a high risk subgroup of 42 subjects based on Minnesota risk score who failed to respond to steroid therapy the OR at day 28 was 48% and 2-year survival in this high risk steroid refractory subgroup was 35%. 8 There are currently no approved therapies specifically indicated for use in steroid-refractory aGVHD in children under the age of 12 years, a patient population with high unmet need and poor prognosis. [8] [9] [10] Acute graft host disease is characterized by immune activation with systemic inflammation and tissue injury primarily affecting the gastrointestinal (GI) tract, skin and liver. Human leukocyte antigen (HLA) disparity between the hematopoietic stem cell (HSC) donor and recipient is a key driver of aGVHD, causing alloreactive donor T cells, contained in the HSC graft, to recognize the patient's tissues as foreign and thereby trigger an immunological attack. 11 Release of inflammatory cytokines by injured tissues amplifies and sustains the activity of alloreactive donor immune cells, leading to further inflammation and end organ damage. 11 The biological activity of mesenchymal stem cells (MSCs) provides a mechanistic rationale for their investigational use in aGVHD. 12 Evidence from in-vitro studies and animal models indicate that bone marrow-derived MSC have immunosuppressive and immunomodulatory functions. [13] [14] [15] [16] [17] [18] [19] Allogeneic tolerance, inhibition at immune checkpoints, and paracrine signaling are MSC mechanisms particularly relevant to aGVHD. [20] [21] Results from initial clinical studies of MSCs have indicated favorable clinical response rates with an acceptable safety profile when used to treat SR-aGvHD. [22] [23] [24] [25] [26] In addition, GVHD therapy with MSCs is associated with reductions in relevant inflammatory biomarkers including IL-2Ra, TNFR1, IL-8 and HGF, providing further evidence of the biological basis of the clinical benefit of this therapy in aGVHD. 25 In a multicenter expanded access protocol using remestemcel-L (Protocol 275, NCT00759018), 241 pediatric subjects with SR-aGVHD, the majority of which were resistant to multiple immunosuppressive therapy (IST) as aGVHD treatment at the time of study enrollment were treated with remestemcel-L, (ex-vivo culture-expanded allogeneic adult human MSC) as salvage therapy for SR-aGVHD. 26 Day 28 OR was 65% (95% CI: 58.9%, 70.9%) and responder survival at day 100 in subjects with a day 28 OR was significantly greater compared to non-responders (82% vs. 39%, log rank p<0.001). Infusions were well tolerated with no identified safety concerns. The present phase 3 registration study was designed to confirm previous observations from a pediatric expanded access program and further evaluate the efficacy and safety of remestemcel-L in children with high risk, steroid refractory aGVHD.
MATERIALS AND METHODS

Study Design
This study (MSB-GVHD001, NCT02336230, IND 7939), a phase 3, single arm, open label, prospective, multicenter study conducted at 20 centers in the US, was designed to evaluate the efficacy and safety of remestemcel-L in pediatric subjects with primary SR-aGVHD in the absence of additional immunosuppressive therapy (IST) for aGVHD. It also included a follow-up safety extension study MSB-GVHD002, to evaluate safety, survival, and duration of response through 180 days.
The design of the study is shown in Figure 1 . Based on ethical and feasibility considerations the study used a single arm design with all subjects receiving remestemcel-L treatment. Feedback from investigators and key experts in pediatric aGVHD indicated that a randomized, controlled study design would be challenging to enroll and potentially unfeasible because parents might be reluctant to consent to participate in a study in which the child might not receive the active investigational therapy. The study was approved by the institutional review boards of the participating centers and was conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines. 29 All participants or legally acceptable representatives provided written informed consent.
Subjects
Children, 2 months to 17 years of age with steroid-refractory grades B to D aGvHD (excluding skin only Grade B) were enrolled from June 2015 to December 2017. Eligible subjects failed to respond to systemic steroid treatment as first line treatment for aGVHD, as defined by progression within three days or no improvement within seven days of consecutive treatment with two mg/kg/day of methylprednisolone or equivalent. Subjects were excluded if they had received any other systemic first line or any second line therapy for the treatment of aGVHD prior to screening or treatment with remestemcel-L. Complete inclusion and exclusion criteria are provided in Supplemental Table S1 .
Investigational Agent
Remestemcel-L is comprised of healthy adult volunteer donor human bone marrow-derived
MSCs that have been ex vivo cultured and, cryopreserved in Plasma-Lyte ® A supplemented with human serum albumin and dimethyl-sulfoxide. Each remestemcel-L dose was stored in the vapor phase of liquid nitrogen, thawed and reconstituted in Plasma-Lyte ® A immediately prior to administration.
MSC are non-hematopoietic cells that express low levels of major histocompatibility complex (MHC) class I, are negative for MHC class II molecules and are negative for co-stimulatory molecules CD40, CD80, and CD86. Remestemcel-L cells are CD105+, CD156+, CD45-, express TNFR1, and suppress IL-2Rα expression on activated lymphocytes. Remestemcel-L cells are harvested at passage five then cryopreserved as final product. In this study, four donors and multiple product lots were used. Most subjects received infusions from more than one lot and some subjects were exposed to cells from more than one donor.
Treatment
Treatment with remestemcel-L was administered to subjects intravenously (IV) at a dose of 2 x 10 6 MSC/kg body weight, twice weekly, for 4 consecutive weeks. All initial therapy infusions were completed by day 28 ± 2 days. Subjects could continue treatment with a stable dose of systemic steroid therapy until eligible for steroid taper per treating physician discretion, and could continue on an established regimen of baseline prophylactic therapy for GVHD. Per protocol, no other medications for the treatment of SR-aGVHD could be introduced to subjects during the initial 28 days of remestemcel-L administration unless disease progression occurred.
Addition of other aGVHD therapies prior to day 28 constituted failure to respond, and the subject remained on study for safety follow-up only.
Subjects with partial (PR) or mixed response (MR) on day 28 could receive continued therapy of four once-weekly infusions of remestemcel-L at the same initial dose of 2 x 10 6 MSC/kg, beginning within one week after the day 28 assessment. Subjects who experienced an aGVHD flare (Grade B-D progression after achieving a complete response (CR)) could receive additional therapy at the same dose twice a week for an additional four weeks.
Assessments of Efficacy and Safety
Acute GVHD assessments were performed at baseline and then weekly from day 14 (±2 days) after the first MSC infusion until day 100 (±7 days). Weekly assessment visits were conducted at least 24 hours after the most recent remestemcel-L infusion. For subjects participating in the follow-up study to day 180, aGVHD assessments were conducted at study visits on days 120, 140, 160 and 180. Severity of aGVHD was evaluated using the CIBMTR grading criteria. [27] [28] All untoward medical occurrences after signing of the informed consent were considered adverse events (AEs). Treatment-emergent adverse events (TEAEs) were those adverse events that occurred after the start of treatment. Serious adverse events (SAE) were defined according to ICH E6 standards. 29 Concomitant medication use was assessed at each visit. Occurrence of chronic GVHD (cGVHD) and relapse of primary disease were assessed through day 180.
Efficacy Endpoints
Definitions of clinical response endpoints are shown in Table 1 . Overall response rate (OR) at day 28 was the primary efficacy endpoint. Day 28 OR is an early indicator of subsequent longerterm response and is now generally accepted as an appropriate surrogate for clinical outcomes. 30 Subjects who were deceased, had missing assessment data, received additional aGVHD IST or withdrew prior to day 28 were considered or imputed as no response (NR) regardless of the responses reported on electronic case report forms (eCRFs). For subjects that were enrolled but not treated with remestemcel-L, the day 28 response was also considered NR. For subjects that withdrew from the study because of a serious adverse event (SAE) or the need for palliative care due to a lack of aGVHD response and had completed a 28 day endpoint assessment, the 28-day assessment was used. The primary study hypothesis was that the primary efficacy endpoint, OR at day 28, is at least 20% greater than the control, standard of care OR of 45%.
Key secondary endpoints were overall and responder survival, and rates of PR, CR, and very good partial response (VGPR), defined as an absence of all GVHD symptoms except Stage 1 disease in any organ. For all enrolled subjects, assessments of vital status through day 100 and day 180 were completed; if vital status was not obtained the subject was presumed to be deceased for the purpose of survival assessment and analysis.
Statistical Analysis
The primary efficacy objective of this study was to confirm the effect of remestemcel-L on day 28 OR. For the assessment of efficacy a treatment effect size of 20% (i.e. 20 percentage points), was considered to be clinically meaningful and was used to calculate the null hypothesis. The null hypothesis of 45% OR for standard of care alone was supported by historical age, and disease severity adjusted published findings and internal data showing an approximate 45% day 28 OR rate for aGVHD subjects treated with steroids, second line systemic agents and supportive symptom management. 31, 32 Details regarding the approximate 45% control overall response rate are provided in Supplemental Table S2 . Kaplan-Meier curves were used to graphically display the data resulting from time-to-event analyses with a log-rank test was used to test for differences across subgroups.
The sample size was determined using East 6.0 software. The hypothesis test used a normal approximation to the binomial distribution under the assumption of a symmetric two-sided one-sample test of the significant level 5% for a single proportion. The minimum sample size required to provide 80% statistical power to demonstrate a 20% treatment difference from a control rate of 45% was 48 subjects. To provide power for additional population analyses and account for premature withdrawals, an increase of 10% to 53 subjects was planned.
Analysis Populations
The primary endpoint and all other efficacy variables were evaluated for all enrolled subjects (n=55), defined as the Full Analysis Set (FAS) population. In this manuscript we present efficacy results on all enrolled subjects that received remestemcel-L treatment (n=54). Safety outcomes were evaluated for all subjects who received at least one dose of remestemcel-L (N=54) for MSB-GVHD001, and all subjects (n=32) that continued into MSB-GVHD002, defined as the Safety population. Duration of response was evaluated in subjects who achieved OR at day 28 in MSB-GVHD001 and subjects enrolled in MSB-GVHD002, which was also defined as the duration of response population. Pre-specified subgroup analyses included those defined by age, gender, aGVHD Grade at baseline, baseline organ involvement, risk stratification, and transplant characteristics.
RESULTS
Subjects
The disposition of subjects is shown in Table 2 . Fifty-five subjects were enrolled on the study and 54 received at least one infusion of remestemcel-L. Of the treated patients, 42 completed treatment and 40 were alive and eligible to enroll on the follow up study on day 100. Of these, 32 subjects enrolled and 31 completed the follow up study to day 180. Thirteen subjects died during the primary study and one subject was lost to follow-up and presumed deceased. In GVHD002 three subjects died and one subject was lost to follow-up and presumed deceased. Table 3 shows baseline demographic and disease characteristics. Briefly, the median age of subjects was 7 years, 63.6% of subjects were male and 76.4% of subjects received an HSCT from an unrelated donor. The source of HSC for transplant was bone marrow (54.5%), peripheral blood stem cell (PBSC) (25.5%) and cord blood in 20% of subjects. The median time from onset of aGVHD to first remestemcel-L infusion was 12 days and median time for establishing onset of steroid failure to first remestemcel-L infusion was 3.5 days. At baseline 47.3% of subjects had Grade D aGVHD, 89.1% had severe disease, defined as Grade C/D and 72.7% of subjects met the criteria for high-risk disease. 33
Exposure
Subject exposure to remestemcel-L is summarized in Table 4 . Thirty subjects received more than the initial 8 infusions (25 subjects for continued therapy and five subjects for aGVHD Flare (9-16 infusions), see Table 4 ). Mean duration of infusions was approximately one hour. The mean dose of MSCs per infusion was approximately 50 x 10 6 cells (median weight 25.5 kg).
Subjects that did not complete the 8 infusions over 28 days) were considered non-responders.
Clinical Response
Clinical response outcomes are summarized in at day 56 to 51.9% at day 100, though this was entirely attributable to an increased CR rate from 29.6% at day 28 to 44.4% at day 100. The median duration of response was 146 days.
Survival
Overall survival was 74.1% (40/54) through day 100 and 68.5% (37/54) at day 180. Kaplan-Meier survival curves are shown in Figure 2 . Survival was statistically superior for day 28 responders compared with non-responders through 100 days (86.8% vs. 47.1%, P=0.0001 log rank) and through 180 days (78.9% vs. 43.8%, p=0.001, Figure 2A ). This finding indicates the strong predictive value of day 28 response to clinical outcome. Survival through day 180 was A total of 30 subjects received additional remestemcel-L therapy: 25 subjects who were partial or mixed responders at day 28 and 5 subjects with GVHD flare following CR. Among the subjects that achieved PR (n=21) or MR (n=2) at day 28 and received continued therapy after day 28, 16/21 (76.2%) and 1/2 (50%) achieved OR at day 56. At day 100, 19 (90.5%) of subjects with PR at day 28 that received continued therapy achieved OR (10 CR plus 9 PR).
The probability of survival at 100 days for subjects receiving initial treatment (four to eight infusions), and continued treatment (9 to 12 infusions), were comparable, 76.2% and 72%, respectively.
Clinical Response within Subgroups
Clinical responses within subgroups based on demographic and disease characteristics are shown in Table 6 . Day 28 OR was consistent across subgroups based on age (0-7, 8-12, and 13-17 years), race (white, non-white) and gender (male and female). Day 28 OR of 43% was lower in peripheral blood transplant recipient than in bone marrow and cord blood transplant recipients: 83% and 73%, respectively. In this study OR in subjects with GVHD grade B was 50%; however, grade B skin only subjects were excluded from this study and the number of grade B subjects was small. Overall response rates at day 28 for grade C and D were 69.6% and 76.0% respectively, and were 86%, 67%, and 63% for skin only, lower GI only, and multi-organ disease, respectively.
Safety
Rates for treatment-emergent adverse events (TEAEs) and serious treatment-emergent adverse events (TESAEs) are summarized in Table 7 . Adverse events of special interest in this study included infusion-related toxicity and ectopic tissue formation as assessed by computed tomography (CT) scans performed at day 180. Infusions were well tolerated with a low incidence of infusion-related events. Three acute infusion reactions were reported in three subjects. Two of these subjects subsequently discontinued infusions and withdrew from the study due to additional TESAEs (somnolence and hypermetabolic syndrome). There was no evidence suggestive of ectopic tissue formation in any subject. During the treatment study MSB-GVHD001 all subjects experienced at least one TEAE, with a total of 99 TESAEs reported in 35 subjects (64.8%). Many of the common TEAEs (occurring in ≥10% of subjects) were conditions related to steroid-refractory aGVHD, infections due to immunosuppressive agents, or steroid toxicities and were not attributed to the study product. Fourteen deaths were recorded within the initial 100 day (+7) period (13 deaths and one subject lost to follow-up and presumed deceased). The primary cause of death was: disease relapse (n=4), aGVHD progression (n=4), infection (n=2), multi-organ failure (n=1), pulmonary hemorrhage (n=1) and cardiac arrest (n=1) and lost to follow-up (n=1). No deaths were causally attributed to remestemcel-L treatment.
Notable shifts in the mean values of monocytes, lymphocytes, neutrophils, bilirubin, and blood glucose were observed over the course of the study. These were expected in a patient population with severe aGvHD requiring multiple supportive medications and not attributed to study product. There were no trends of abnormal safety signals related to other lab values.
While events of skin GVHD, HUS and infections are expected in this disease population and therefore, unlikely causally attributed to remestemcel-L, any potential increase in immune suppression mediated by remestemcel-L could increase the risk of adenovirus and BK virus infections. Overall, steroids were slowly tapered in responding patients which resulted in a decrease in steroid related AEs, further supporting the effectiveness of remestemcel-L therapy.
In the MSB-GVHD002 follow-up study, 27 of 32 subjects (84.4%) experienced one or more TEAE and 15 of 32 (46.9%) experienced any TESAE. No TEAEs or TESAEs were considered treatment-related. Infections were the most common TESAE, with 8 (25%) experiencing serious infections. Two deaths were recorded between day 100 and day 180: one due to recurrent acute lymphocytic leukemia at day 174, and the other was a subject lost to follow-up and presumed deceased. The subject that was enrolled but not treated died on day 189.
Additional follow-up to 180 Days
Of the 32 subjects followed through 180 days in the follow-up study, 15 (46.9%) discontinued systemic corticosteroid use for GVHD treatment by end of study. In addition, most (n=28, 87.5%) subjects were GVHD immunosuppressive therapy (IST) free by day 180. Chronic GVHD was reported in eight subjects during the follow-up study; six cases were mild, one moderate, and one was severe. CMV surveillance testing was conducted during the initial and follow-up study periods. Of all treated subjects; one experienced CMV disease, one experienced sustained reactivation, and four experienced transient reactivations considered to be clinically significant.
There were no infusion-related toxicities and no evidence suggestive of ectopic tissue formation.
DISCUSSION
aGVHD is a major cause of morbidity and mortality in adults and children undergoing HSCT. 2, 4, 7, 8 There is a large unmet need for effective treatment. In previous studies, remestemcel-L treatment showed promising results for the treatment for SR-aGVHD in pediatric subjects. 26, 35, 36 We report here the positive results of a prospective, multicenter, phase 3, pediatric study using remestemcel-L as first line therapy for SR-aGVHD with long-term follow up through 180 days (MSB-GVHD002). At day 28 remestemcel-L treated subjects achieved statistically superior OR compared to the pre-specified control rate (70.4% versus 45%, P=0.0003, binomial proportion p-value), demonstrating a clinically meaningful treatment effect greater than 20 percentage point treatment difference. The high OR was sustained at day 100 (70.4%), meeting study-defined endpoints and confirming previously reported remestemcel-L response rates in SR-aGVHD.
Survival through day 100 was also significantly greater for day 28 responders than nonresponders (86.8% versus 47.1%, (P< 0.0001 log rank). Superior survival with remestemcel-L treatment was sustained through day 180 in subjects with a day 28 OR with 78.9% compared with 43.8% for responders and non-responders, respectively (P=0.001 log rank). Overall survival through day 100 (74.1%) and day 180 (68.5%) with remestemcel-L treatment is a meaningful increment compared with overall 2-year overall survival of 34% with standard of care in aGVHD patients <18 years old as reported by Rashidi et al. 7 A trend for greater response was observed in in aGVHD Grade C and Grade D than in Grade B subjects; in other words, in subjects with more severe disease and higher mortality risk. This finding is consistent with a report that the potent anti-inflammatory and immunosuppressive properties of mesenchymal stromal cells are induced by exposure to high levels of specific cytokines. 37, 38 Further research may elucidate this hypothesis which is consistent with our clinical findings of increased rates of OR and OS in the presence of more severe aGVHD as defined both by risk stratification and aGVHD grade.
The clinical response to remestemcel-L treatment at day 28 was significantly associated with improved survival through day 180 thus demonstrating the strong predictive value of this endpoint for subsequent clinical benefit. The median duration of response for responders who enrolled in the safety follow up study was 146 days, demonstrating durability of response to remestemcel-L. 35 Our results are also compatible with findings reported in a pediatric subset of steroid-refractory aGVHD subjects in a randomized controlled trial of remestemcel-L versus placebo (n=14 per group) added on to standard of care. In this study OR at day 28 was 64% and 36% in the remestemcel-L and placebo-treated children, respectively. 36 Overall response and overall survival through day 180 of the follow up study were consistent across subgroups based on baseline demographic factors: none of these factors substantially influenced overall response rate or overall survival through day 180. Greater overall response was observed in bone marrow and cord blood transplant recipients compared with recipients of PBSC grafts, although the clinical significance of this finding is unclear. Consistent responses were also observed across involved organs.
Results of this study indicate that remestemcel-L is effective, safe and well-tolerated for the treatment of steroid-refractory aGVHD in pediatric subjects, with the majority of reported adverse events attributable to the subjects' underlying disease or its treatment. Adverse events designated by the investigators as possibly related to remestemcel-L were mostly mild to moderate in severity and not clearly related to the study drug. Although a few serious treatmentrelated events were observed, these generally resolved without sequelae. Complications of aGVHD and/or relapse were the primary causes of death. Relapse was a leading cause of death in non-responders. Chronic GVHD was reported during the follow-up study, in most cases was mild and did not appear to impact survival through day 180, although this time-point is too early to know the impact of remestemcel-L treatment for aGVHD on chronic GVHD. Clinical manifestations of significant CMV viral load were monitored and most patients remained free of CMV reactivation throughout the study. There were no cases of ectopic tissue formation.
Importantly, remestemcel-L did not show hematologic, immunologic or renal toxicity and therefore does not overlap with known toxicities of other commonly used agents to treat SR aGVHD.
A number of studies have assessed the safety and efficacy of cell therapies in adults with GVHD, as described in the recent meta-analysis. 39 subject attributes such as severity of disease and organ involvement. The impact of several of these factors are described by Kebriaei et al. 40 In this randomized controlled trial of remestemcel-L vs. placebo in both adults and children with aGVHD, among high-risk adult subjects, remestemcel-L treatment produced significantly higher OR at day 28 compared to placebo (58% vs. 37%; p=0.03) and similarly improved day 28 OR compared to placebo in the pediatric subset (64% vs. 23%; p=0.05). 40 The present study achieved its primary objectives of demonstrating that remestemcel-L infusions significantly improved overall response in SR-aGVHD pediatric subjects compared with derived historical rates and were well tolerated with no identified safety concerns. In addition, the observed improved response at day 28 was strongly associated with significantly improved survival through day 180. Few subjects received additional IST therapy for aGVHD during this study, further evidence of remestemcel-L effectiveness in aGVHD symptom control. Results of this study confirm the overall response, safety, and survival demonstrated in a pediatric expanded access program study that assessed remestemcel-L in children who failed to respond to steroids and additional immunosuppressive agents for the treatment of aGVHD. 26, 35 In conclusion, MSB-GVHD001 and the MSB-GVHD002 follow up study taken together with positive findings of other remestemcel-L studies in aGVHD 26, 36, 40 confirm the safety profile and demonstrate the efficacy and durability of remestemcel-L treatment for SR-aGVHD in the pediatric population. 1 Responses are based on the number of subjects that received remestemcel-L treatment (n=54) Values are number (percent) of subjects reporting the event. Percentage was calculated using the number of subjects in the column heading as the denominator.
* TEAEs are adverse events that started on or after the dose date of study treatment †As assessed by the investigator ‡ Subject may have had more than one TEAE or TESAE but is counted only once within a system organ class category 
